An approved drug normally used to treat fungal infections could also do the job of a protein channel that is missing in the lungs of people with cystic fibrosis, operating as a prosthesis on the molecular scale, says new research from the University of Illinois and the University of Iowa. Cystic fibrosis is a lifelong
Schoolboy, 8, is ‘living with a death sentence’ because the NHS won’t fork out for £100,000-per-year cystic fibrosis ‘wonder drug’ George Monckton could be saved from lung deterioration by Orkambi It could extend the lives of patients who often die before reaching middle age Drug is unavailable on NHS because of a deadlock in price
The majority of patients with cystic fibrosis may not achieve blood concentrations of antibiotics sufficiently high enough to effectively fight bacteria responsible for pulmonary exacerbations, leading to worsening pulmonary function, indicates a study led by researchers at Children’s National Health System. Additionally, the study findings show that it’s impossible to predict solely from dosing regimens
A new triple-combination drug treatment being trialled at the Mater Hospital in Brisbane could increase the life expectancy of patients with cystic fibrosis. Mater Research Institute-University of Queensland (MRI-UQ) researcher Dr. Lucy Burr said seven patients were enrolled in Phase 2 of the clinical trial, which aimed to treat the underlying cause of cystic fibrosis.
THURSDAY, Oct. 18, 2018 — In what researchers are calling a “breakthrough,” two preliminary trials have found that either of two triple-drug regimens could potentially benefit 90 percent of people with cystic fibrosis. The trials were short-term, finding that the drug combinations improved adult patients’ lung function over four weeks. But experts said they were